Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Table 4 Univariable and Multivariate analysis for OS in Fudan Cohort.

Variables		Univariate			Multivariate		
		P value	HR	95%CI	P value	HR	95%CI
Age							
	≥60 vs. <60	**0.066**	**1.60**	**0.97 - 2.64**	0.280	1.333	0.79 -2.24
FIGO staging							
	III-IV vs. I-II	**0.001**	**4.64**	**1.85 - 11.55**	**0.009**	**3.54**	**1.37 -9.15**
Lymph node invasion							
	Yes vs. No	**0.025**	**1.83**	**1.078 - 3.12**	0.296	1.355	0.77-2.38
Tumor residual							
	>10mm vs. ≤10mm	0.107	1.58	0.91 - 2.71			
PD-L1							
	Positive vs. Negative	**0.007**	**0.45**	**0.25 - 0.80**	**0.005**	**0.430**	**0.24-0.77**
Siglec-9+TAMs							
	High vs. Low	**0.048**	**1.66**	**1.01 - 2.732**	**0.048**	**1.672**	**1.01-2.78**
Siglec-9 ligand							
	High vs. Low	0.884	0.97	0.59 - 1.58			
CD163							
	High vs. Low	**0.037**	**1.72**	**1.03 - 2.87**	0.210	1.412	0.88-2.43
CD68							
	High vs. Low	0.281	1.41	0.753 - 2.65			

Abbreviations: HR, Hazard ratio; 95% CI,95% Confidence intervals.

Abbreviation: HR, Hazard Ratio; CI: confidence i

*Multivariate Cox regression analysis beyond risk score.

Statistically significant data were marked with bold and underline.